ReviewBiomedicines2022
The Role of miR-29s in Human Cancers-An Update.
Review in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- tRNA-derived fragments: mechanism of gene regulation and clinical application in lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2024Pooled it
- Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.Leukemia · 2026Trial
- Loss of miR-29a/b1 Cluster Reprograms the Tumor Microenvironment and Contributes to Immunosuppression in Lung Cancer.Cancer immunology research · 2026Article
- Epigenetic Biomarkers for Predicting Nucleoside Analog Drug Response and Resistance in Cancer.Biomolecules · 2026Review
- Leveraging extracellular vesicle biology for novel tests and therapeutics for kidney fibrosis.Clinical and translational medicine · 2026Review
- Article
- Expression patterns of miR-221, miR-214, and miR-375 in odontogenic keratocysts versus dentigerous cysts: an in vitro comparison.BMC oral health · 2025Article
- Molecular profiling and bioinformatics validation of CEACAM6, HOXA-AS3 and miR29a in colorectal cancer.Scientific reports · 2025Article
- HypoxamiRs: the hidden architects of tissue adaptation in hypoxia.Cell death & disease · 2025Review
- Micro RNA in Colorectal Cancer-Potential Diagnostic and Prognostic Markers-An Updated Review.International journal of molecular sciences · 2025Review
- Review
- MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer.Cancers · 2025Article
- Diagnostic and Therapeutic Potential of Selected microRNAs in Colorectal Cancer: A Literature Review.Cancers · 2025Review
- Article
- Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.Scientific reports · 2025Article
- Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.International journal of molecular sciences · 2024Review
- Therapeutic combinations of exosomes alongside cancer stem cells (CSCs) and of CSC-derived exosomes (CSCEXs) in cancer therapy.Cancer cell international · 2024Review
- Review
- miR-29a-3p orchestrates key signaling pathways for enhanced migration of human mesenchymal stem cells.Cell communication and signaling : CCS · 2024Article
- How MicroRNAs Command the Battle against Cancer.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that directly bind to the 3' untranslated region (3'-UTR) of the target mRNAs to inhibit their expression. The miRNA-29s (miR-29s) are suggested to be either tumor suppressors or oncogenic miRNAs that are strongly dysregulated in various types of cancer. Their dysregulation alters the expression of their target genes, thereby exerting influence on different cellular pathways including cell proliferation, apoptosis, migration, and invasion, thereby contributing to carcinogenesis. In the present review, we aimed to provide an overview of the current knowledge on the miR-29s biological network and its functions in cancer, as well as its current and potential applications as a diagnostic and prognostic biomarker and/or a therapeutic target in major types of human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.